Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

62.66 -1.53 (-2.38%)

Delayed Quote Updated: 11:25 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones

November 09, 2022

From Royalty Pharma plc

Via GlobeNewswire

Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones

November 09, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline

November 07, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

October 13, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3

October 11, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences

September 01, 2022

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis

August 17, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗

September 09, 2022

Upgrades

Via Benzinga

What 7 Analyst Ratings Have To Say About Arrowhead Pharmaceuticals ↗

August 08, 2022

Analysts have provided the following ratings for Arrowhead Pharmaceuticals (NASDAQ:ARWR) within the last quarter:

Via Benzinga

Arrowhead Pharmaceuticals: Q3 Earnings Insights ↗

August 04, 2022

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q3 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results

August 04, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results

July 20, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 08, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE

July 05, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences

June 07, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics

May 26, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Where Arrowhead Pharmaceuticals Stands With Analysts ↗

May 24, 2022

Within the last quarter, Arrowhead Pharmaceuticals (NASDAQ:ARWR) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022 ↗

May 11, 2022

Upgrades

Via Benzinga

Arrowhead Pharmaceuticals: Q2 Earnings Insights ↗

May 10, 2022

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q2 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results

May 10, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives

May 09, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors

May 02, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences

May 02, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Week In Review: I-Mab Files For Hong Kong SPAC IPO To Acquire Life Science Company ↗

April 30, 2022

I-Mab and one of its investors, VMS, have filed for a Hong Kong IPO of a SPAC that will raise funds to acquire a life science company. Also, RVAC Medicines completed a Series B funding that brings...

Via Talk Markets

Arrowhead Pharmaceuticals to Host Pulmonary R&D Day

April 27, 2022

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia

April 26, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market

April 25, 2022

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More ↗

April 24, 2022

Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...

Via Benzinga

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results

April 20, 2022

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.